Plasminogen antibodies: a "new clue" in anti-neutrophil cytoplasmic antibody-associated vasculitis

Plasminogen antibodies: a "new clue" in anti-neutrophil cytoplasmic antibody-associated vasculitis

In the human body's complex immune system, antibodies play a vital role. They are the body's "guards" against pathogen invasion. However, sometimes antibodies can also become abnormal, leading to the occurrence of autoimmune diseases. Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is such a disease, and plasminogen antibodies (anti-plasminogen antibodies) are a "new clue" that has attracted much attention in AAV research in recent years.
AAV: A complex autoimmune disease

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a group of rare autoimmune diseases, mainly including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases are characterized by inflammation of small to medium-sized blood vessels and affect multiple organ systems, with the kidneys and lungs being the most commonly affected organs. The course of AAV is complex and variable, and patients may experience repeated attacks and remissions of the disease, and even cause serious organ damage. At present, although some progress has been made in the treatment of AAV, it still faces many challenges, such as complications caused by treatment, risk of disease recurrence, and lack of effective biomarkers to predict treatment response and disease progression.
Plasminogen antibodies: "new discovery" in AAV

In addition to the common anti-neutrophil cytoplasmic antibodies (ANCA) in AAV patients, scientists have also found the presence of some other antibodies, among which plasminogen antibodies are a potential biomarker. Plasminogen is a key protein in the fibrinolytic system, which plays an important role in maintaining the balance of blood coagulation and dissolution. Studies have found that the positive rate of plasminogen antibodies in AAV patients is relatively high, especially in the active stage of the disease. For example, in the AAV patient population in the UK and the Netherlands, this antibody can be detected in about 24%-26% of patients, while in the healthy control population, this proportion is only 2%. In addition, similar results have been found in the study of AAV patients in China, with 18% of patients in the active stage of the disease having plasminogen antibodies, while in patients in remission, this proportion is only 2%.
Relationship between plasminogen antibodies and disease

The presence of plasminogen antibodies is closely related to the disease activity of AAV. Studies have shown that there is an association between the titer of this antibody and the erythrocyte sedimentation rate, renal function, and certain renal biopsy characteristics. In some patients, the appearance of plasminogen antibodies is also associated with a prolonged fibrinolysis process, which may further aggravate kidney damage. In addition, the level of plasminogen antibodies is higher during the active stage of the disease and decreases significantly during the remission period. This suggests that plasminogen antibodies may be involved in the pathogenesis of AAV and play a role in the progression of the disease.
Clinical significance of plasminogen antibodies

Although plasminogen antibodies have a certain positive rate and evidence of association with disease activity in AAV patients, they cannot currently be used as a specific diagnostic marker for AAV. This is because this antibody may also be expressed at low levels in some healthy people, and its positive rate varies in different populations. However, the detection of plasminogen antibodies still has important clinical significance. First, it can be used as an auxiliary diagnostic indicator to help doctors evaluate the patient's condition more comprehensively. Second, for those patients who are positive for plasminogen antibodies, doctors can pay more attention to their disease progression and treatment response and adjust the treatment plan in time. In addition, the study of plasminogen antibodies also provides a new perspective on the pathogenesis of AAV and helps to develop new treatments.
Directions for future research

Although the role of plasminogen antibodies in AAV has attracted widespread attention, there are still many questions that need further study. For example, what is the specific pathogenic mechanism of this antibody? Is there a synergistic effect between it and other antibodies (such as ANCA)? In addition, it is necessary to verify in a larger patient population to determine the positive rate and clinical significance of plasminogen antibodies in different races and disease subtypes. At the same time, studying its value in predicting disease recurrence is also an important direction in the future. By in-depth research on plasminogen antibodies, we hope to better understand the pathogenesis of AAV and provide patients with more accurate diagnosis and treatment.

Conclusion

As a "new clue" in AAV research, plasminogen antibodies provide us with new ideas and directions. Although it cannot completely replace traditional biomarkers at present, its potential value in disease diagnosis, disease monitoring and pathogenesis research cannot be ignored. With the continuous deepening of research, it is believed that plasminogen antibodies will play a more important role in the clinical practice of AAV and bring more hope and help to patients.